New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
The Greater Cannabis Company, Inc.
GCAN
Shape
US Flag

PNK

Unprofitable

EPS improving

Unprofitable

EPS improving

402319

Drug Manufacturers - Specialty & Generic

0.00USD
0.00 ( 0.00%)
Market Open
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

-28%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

100%
OverviewChart

Quote Panel

Shape
Updated October 21, 2024
1W 0.00 % 1M -16.67 % 3M -28.57 % 1Y -16.67 %

Key Metrics

Shape

  • Market Cap

    402319

  • Shares Outstanding

    804.64M

  • Share in Float

    795.15M

  • Dividende

    0

  • Earning Date

    No Data

  • Price Target

    0.0005

  • Average Volume

    1.58M

  • Beta

    1.616

  • Range

    4.0E-4-0.0015

  • Industry

    Drug Manufacturers - Specialty & Generic

  • Website

    https://www.gcanrx.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

-0.54x

P/B Ratio

-0.6

Debt/Equity

0.0%

Net Margin

$0.0

EPS

How GCAN compares to sector?

P/E Ratio

GCAN

-2x

GBHPF 0x
CSUI -1x
MGWFF -6x
MSMY -23x
TMSH -4x

Relative Strength

Shape

GCAN

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

NA
vs NA

Q3.22

arrow
arrow

N/A

NA
vs NA

Q4.22

arrow
arrow

N/A

NA
vs NA

Q1.23

arrow
arrow

N/A

-0.00
vs NA

Q2.23

arrow
arrow

N/A

-0.00
vs NA

Q3.23

arrow
arrow

N/A

-0.00
vs NA

Q4.23

arrow
arrow

N/A

NA
vs NA

Q1.24

arrow
arrow

N/A

NA
vs -0.00

Q2.24

arrow
arrow

N/A

NA
vs -0.00

Q3.24

arrow
arrow

+2202114%

1.54
vs -0.00

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.22

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

-100%

NA  vs 12.6K

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

+28%

0.28
vs 0.13

Q4.22

arrow
arrow

+10%

0.1
vs 0.28

Q1.23

arrow
arrow

+8%

0.08
vs 0.1

Q2.23

arrow
arrow

+7%

0.07
vs 0.08

Q3.23

arrow
arrow

+8%

0.08
vs 0.07

Q4.23

arrow
arrow

+7%

0.07
vs 0.08

Q1.24

arrow
arrow

+6%

0.06
vs 0.07

Q2.24

arrow
arrow

+6%

0.06
vs 0.06

Institutionnal OwnershipShape

status-upQoQ

Q1.19

arrow
arrow

1

1
vs NA

NA

Q2.19

arrow
arrow

1

1
vs 1

NA

Earnings Growth

Latest News

GCAN

https://www.defenseworld.net

5 hours ago

Koninklijke Philips (NYSE:PHG) Shares Sold by National Bank of Canada FI
GCAN

https://www.defenseworld.net

7 hours ago

Dimensional Fund Advisors LP Purchases 140,347 Shares of Tapestry, Inc. (NYSE:TPR)
GCAN

globenewswire.com

7 hours ago

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
GCAN

https://www.defenseworld.net

8 hours ago

Meridian Wealth Management LLC Makes New Investment in InterContinental Hotels Group PLC (NYSE:IHG)
GCAN

globenewswire.com

8 hours ago

GCANRx Featured in American Journal of Endocannabinoid Medicine
GCAN

globenewswire.com

9 hours ago

GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy

New Feature Coming Soon, Stay Tuned!

ShapeShape